CMC

CATUG and Crystal Bio Establish Strategic Partnership, Launching "CATUG-Crystal" Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services

Retrieved on: 
Thursday, February 22, 2024
Therapy, Messenger, Drug development, Spacecraft, Antibody, RNA, Peptide, Dicarboxylic acid, Organization, Protein, DNA, CMC, Partnership, Fine chemical

and CRANBURY, N.J., Feb. 22, 2024 /PRNewswire/ -- CATUG Inc. (CATUG) and Crystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to provide advanced nucleic acid-based drug analytical services.

Key Points: 
  • and CRANBURY, N.J., Feb. 22, 2024 /PRNewswire/ -- CATUG Inc. (CATUG) and Crystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to provide advanced nucleic acid-based drug analytical services.
  • CATUG, a distinguished global entity specializing in integrated nucleic acid and drug delivery CRDMO services, is combining capabilities with Crystal Bio, a premier provider of analytical services for biologics in CMC, preclinical development, and clinical stages.
  • The two specialized organizations will provide clients with comprehensive nucleic acid services and analytical solutions in the North American market.
  • CATUG and Crystal Bio are confident that by combining the local analytical prowess of Crystal Bio with CATUG's proficient expertise in integrated nucleic acids analytical platforms, CATUG-Crystal will deliver best-in-class analytical services and drive advancements in nucleic acid-based drug development to the North American market.

CMC Announces Second Quarter Fiscal 2024 Conference Call Webcast Details

Retrieved on: 
Wednesday, February 21, 2024
CFO, Senior, Commercial Metals Company, Webcast, Internet, CMC

IRVING, Texas, Feb. 21, 2024 /PRNewswire/ -- Commercial Metals Company (NYSE: CMC), in conjunction with its second quarter earnings release for fiscal 2024, invites you to listen to its conference call that will be broadcast live over the Internet on Thursday, March 21, 2024, at 11:00 a.m. Eastern Time (10:00 a.m. Central) with Peter Matt, President and CEO, and Paul Lawrence, Senior Vice President & CFO.

Key Points: 
  • IRVING, Texas, Feb. 21, 2024 /PRNewswire/ -- Commercial Metals Company (NYSE: CMC), in conjunction with its second quarter earnings release for fiscal 2024, invites you to listen to its conference call that will be broadcast live over the Internet on Thursday, March 21, 2024, at 11:00 a.m. Eastern Time (10:00 a.m. Central) with Peter Matt, President and CEO, and Paul Lawrence, Senior Vice President & CFO.
  • The teleconference will also be available via webcast.
  • To access the webcast (in listen-only mode), please visit CMC's Web site at www.cmc.com .

CMC Announces Appointment of Dennis V. Arriola to Board of Directors

Retrieved on: 
Tuesday, February 20, 2024
Audit, Investment, Meritage Homes Corporation, Harvard University, Car, Stanford University, Commercial, ConocoPhillips, SunPower, Business administration, Sempra, Master, Commercial Metals Company, CMC, Management

IRVING, Texas, Feb. 20, 2024 /PRNewswire/ -- Commercial Metals Company (NYSE: CMC) today announced that it has named Dennis V. Arriola to the Board of Directors, effective as of March 19, 2024.

Key Points: 
  • IRVING, Texas, Feb. 20, 2024 /PRNewswire/ -- Commercial Metals Company (NYSE: CMC) today announced that it has named Dennis V. Arriola to the Board of Directors, effective as of March 19, 2024.
  • He also serves on the Board of Directors of ConocoPhillips, Meritage Homes and the Automobile Club of Southern California.
  • "We are pleased to welcome Dennis to our Board of Directors," said Barbara R. Smith, Executive Chairman of the Board.
  • Mr. Arriola received a Bachelor of Arts in Economics from Stanford University and a Masters of Business Administration from Harvard University.

Claremont McKenna College named "Top Producing Institution" of Fulbright Students by U.S. Secretary of State

Retrieved on: 
Thursday, February 15, 2024
Claremont McKenna College, Second Continental Congress, College, Ethics, Climate change, Student, Teaching, Congress, Host, Fellow, Research, CMC, Nursing

CLAREMONT, Calif., Feb. 15, 2024 /PRNewswire/ -- In a recent congratulatory letter to Claremont McKenna College President Hiram Chodosh, U.S. Secretary of State, the Honorable Anthony J. Blinken, designated Claremont McKenna College a "Top Producing Institution" of Fulbright U.S. Students for 2023-2024.

Key Points: 
  • CLAREMONT, Calif., Feb. 15, 2024 /PRNewswire/ -- In a recent congratulatory letter to Claremont McKenna College President Hiram Chodosh, U.S. Secretary of State, the Honorable Anthony J. Blinken, designated Claremont McKenna College a "Top Producing Institution" of Fulbright U.S. Students for 2023-2024.
  • Fulbright seeks students of the world who have a strong interest in cross-cultural exchange, research, or teaching opportunities overseas.
  • Claremont McKenna ranked as a top-tier institution among colleges and universities nationwide, with 106 of the College's students achieving the distinction as Fulbright Students throughout the school's history.
  • "I'm delighted by the fact that Claremont McKenna has once again been recognized as a Top Producing Institution of Fulbright recipients," said Brian Davidson '08, Director of Fellowship Advising at Claremont McKenna.

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Retrieved on: 
Wednesday, February 14, 2024
AmerisourceBergen, EMA, Injection, Committee, Fiscal, CRL, Outlook, MAA, Ranibizumab, FDA, Calendar, Completion, Bevacizumab, Symantec Endpoint Protection, Chemistry, Therapy, CHMP, European Medicines Agency, AMD, Patient, SPA, Retina, CMC

ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.

Key Points: 
  • ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.
  • Importantly, the first subject was enrolled in NORSE EIGHT in January 2024,” commented Russell Trenary, President and Chief Executive Officer.
  • In January 2024, Outlook Therapeutics announced that it received written agreement on the NORSE EIGHT trial protocol from the FDA under a SPA for NORSE EIGHT.
  • Outlook Therapeutics expects NORSE EIGHT topline results and resubmission of the ONS-5010 BLA by the end of calendar year 2024.

Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer

Retrieved on: 
Wednesday, February 14, 2024
Therapy, Neoplasm, Senior, Cancer, Discovery, Co-promotion, Patient, CMC, Partnership, Pharmaceutical industry

HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.

Key Points: 
  • HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.
  • Under the terms of the agreement, Ono has obtained an option to in-license NM49 from Numab for global development and commercialization, with Numab retaining an option to co-develop and commercialize in the United States.
  • “This important partnership marks our third collaboration with Ono and the first one where Numab has the option to co-develop and commercialize in the United States.
  • We are thrilled to continue working with Ono on developing new high impact multi-specific therapeutics for cancer patients,” said David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics.

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

Retrieved on: 
Tuesday, February 13, 2024
Metronidazole, Toxicology, New Drug Application, Research, Paromomycin, FDA, TSX, Drug development, Infection, Dysphagia, Sale, Skin, Government, USAFA, Indian stock exchange, Patent, Patient, Pharming, IND, Bank statement, CMC, Pharmaceutical industry

HALIFAX, Nova Scotia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the third quarter of its fiscal year 2024, which ended on December 31, 2023. All figures are stated in Canadian dollars unless otherwise stated.

Key Points: 
  • In September 2023, Appili announced the FDA approval of LIKMEZ™ (ATI-1501) , our proprietary taste-masked liquid suspension reformulation of metronidazole, through our U.S. partner, Saptalis Pharmaceuticals LLC.
  • Collaborating with Saptalis, Appili earned US$600,000 in milestone payments in fiscal 2024.
  • Appili was granted a pre-IND meeting with the FDA to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies and expects to receive feedback in early 2024.
  • As of February 13, 2024, the Company had 121,266,120 issued and outstanding Common Shares, 7,957,000 stock options, and 44,856,874 warrants outstanding.

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

Retrieved on: 
Tuesday, February 13, 2024
SAN, Pharmacy, RAPT, Drug development, MBA, Hypoxia, Inflammation, Doctor of Philosophy, University, Therapy, Business, Patient, Astex Pharmaceuticals, CMC, Pharmaceutical industry

“I am delighted to announce the addition of Nipun to the RAPT leadership team and welcome his wealth of experience in small molecule product development and commercial manufacturing,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics.

Key Points: 
  • “I am delighted to announce the addition of Nipun to the RAPT leadership team and welcome his wealth of experience in small molecule product development and commercial manufacturing,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics.
  • Nipun brings over 27 years of extensive biopharmaceutical and drug development experience specializing in successful product development and commercial manufacturing.
  • Nipun holds a Ph.D. in Pharmaceutical Sciences from the University of Maryland and an MBA from the Wharton School of Business.
  • Nipun added, "I am pleased to join the RAPT leadership team during this exciting period.

Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia

Retrieved on: 
Tuesday, February 13, 2024
Fibromyalgia, Tonix Pharmaceuticals, New Drug Application, FDA, Food, Overalls, Hydrogen chloride, Fatigue, Tablet, NDA, CMC, Rho, Pharmaceutical industry

CHATHAM, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) --  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has engaged Rho, Inc. (Rho), a global contract research organization (CRO), to support Tonix’s preparation and planned submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia.

Key Points: 
  • “We intend to meet with the FDA in the first half of this year and to submit our NDA in the second half of the year.
  • In the study, Tonmya met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.
  • “We are delighted in our continued support of Tonix and their Tonmya program,” said Tara Gladwell, President and COO at Rho.
  • “We are hopeful that this work may result in a new treatment for the millions of Americans that suffer from this debilitating, chronic disorder.”

Cielo Provides Update on Continued Progress and Milestones Achieved to Advance Carseland Bio-SynDiesel® Project

Retrieved on: 
Tuesday, February 13, 2024
Acquisition, Engineering, Cielo, Wood, CMC, Expander, ECCO, Biomass, Carbon, Municipal solid waste, NEWS, Protected area, Oil

CALGARY, Alberta, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV: CMC; OTC: CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging environmental technology to produce renewable fuel from wood by-products, is pleased to share an update on its Carseland, Alberta Bio-SynDiesel® Project (the “Carseland Project”).

Key Points: 
  • CALGARY, Alberta, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV: CMC; OTC: CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging environmental technology to produce renewable fuel from wood by-products, is pleased to share an update on its Carseland, Alberta Bio-SynDiesel® Project (the “Carseland Project”).
  • Once completed, the Carseland Project represents Cielo’s first commercial by-product-to-fuels facility designed to convert wood by-products into low carbon intensity renewable Bio-SynDiesel® fuel.
  • This contract provides Cielo with an ongoing and cost-effective supply of the requisite biomass feedstock for the Carseland Project.
  • Cielo looks forward to providing continued updates as further progress is made and milestones are achieved.